Pauline Trémeaux1, Sébastien Lhomme2, Sabine Chapuy-Regaud2, Jean-Marie Peron3, Laurent Alric4, Nassim Kamar5, Jacques Izopet2, Florence Abravanel6. 1. CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France. 2. CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France. 3. CHU Toulouse, Hôpital Purpan, Département de Gastroentérologie, F-31300, France. 4. CHU Toulouse, Hôpital Purpan, Service de Médecine Interne, F-31300, France. 5. CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; CHU Toulouse, Hôpital Rangueil, Département de Néphrologie, Dialyse et Transplantation multi-organe, F-31300, France. 6. CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France; INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France. Electronic address: abravanel.f@chu-toulouse.fr.
Abstract
BACKGROUND: Hepatitis E virus (HEV) is a major cause of hepatitis worldwide. Its diagnosis is based on the detection of anti-HEV IgM and/or HEV-RNA. OBJECTIVE: To evaluate the performance of the Wantaï HEV-antigen (Ag) ELISA(Plus) assay for diagnosing acute HEV infections. STUDY DESIGN: Specificity was assessed using 100 blood samples containing no anti-HEV IgM, anti-HEV IgG, or HEV-RNA. Cross reactivity was assessed using samples positive for hepatitis C virus RNA (n=10), Epstein-Barr virus DNA (n=10) and cytomegalovirus DNA (n=10). Serial dilutions of 4 HEV RNA positive samples were used to estimate the corresponding viremia detected with the Ag assay. Blood samples from 33 immunocompetent and 31 immunocompromised patients with an acute HEV genotype 3 infection, HEV-RNA positive, were tested to assess diagnostic sensitivity. RESULTS: The HEV-Ag assay was 100% specific, with no cross-reactivity. The lower viremias detected ranged from 10(3)copies/ml to 10(5)copies/ml (800-80,000UI/ml). Diagnostic sensitivity for an acute HEV infection was 91%, with no significant difference between immunocompetent (88%) and immunocompromised (94%) patients. The HEV-Ag assay was more frequently positive in immunocompromised patients at the acute phase (94%) than was the anti-HEV IgM test (71%; p=0.04). The HEV-Ag assay ratio was correlated with HEV-RNA viral load (ρ=0.54; p<0.0001). CONCLUSION: The HEV-Ag assay performed well and could be suitable for laboratories with no molecular diagnosic facilities.
BACKGROUND:Hepatitis E virus (HEV) is a major cause of hepatitis worldwide. Its diagnosis is based on the detection of anti-HEV IgM and/or HEV-RNA. OBJECTIVE: To evaluate the performance of the Wantaï HEV-antigen (Ag) ELISA(Plus) assay for diagnosing acute HEV infections. STUDY DESIGN: Specificity was assessed using 100 blood samples containing no anti-HEV IgM, anti-HEV IgG, or HEV-RNA. Cross reactivity was assessed using samples positive for hepatitis C virus RNA (n=10), Epstein-Barr virus DNA (n=10) and cytomegalovirus DNA (n=10). Serial dilutions of 4 HEV RNA positive samples were used to estimate the corresponding viremia detected with the Ag assay. Blood samples from 33 immunocompetent and 31 immunocompromised patients with an acute HEV genotype 3 infection, HEV-RNA positive, were tested to assess diagnostic sensitivity. RESULTS: The HEV-Ag assay was 100% specific, with no cross-reactivity. The lower viremias detected ranged from 10(3)copies/ml to 10(5)copies/ml (800-80,000UI/ml). Diagnostic sensitivity for an acute HEV infection was 91%, with no significant difference between immunocompetent (88%) and immunocompromised (94%) patients. The HEV-Ag assay was more frequently positive in immunocompromised patients at the acute phase (94%) than was the anti-HEV IgM test (71%; p=0.04). The HEV-Ag assay ratio was correlated with HEV-RNA viral load (ρ=0.54; p<0.0001). CONCLUSION: The HEV-Ag assay performed well and could be suitable for laboratories with no molecular diagnosic facilities.
Authors: Mohamed A El-Mokhtar; Haidi Karam-Allah Ramadan; Muhamad R Abdel Hameed; Ayat M Kamel; Sahar A Mandour; Maha Ali; Mohamed A Y Abdel-Malek; Doaa M Abd El-Kareem; Sara Adel; Eman H Salama; Khaled Abo Bakr Khalaf; Ibrahim M Sayed Journal: Virulence Date: 2021-12 Impact factor: 5.882
Authors: Montserrat Elemi García-Hernández; Mayra Cruz-Rivera; José Iván Sánchez-Betancourt; Oscar Rico-Chávez; Arely Vergara-Castañeda; María E Trujillo; Rosa Elena Sarmiento-Silva Journal: BMC Vet Res Date: 2017-09-21 Impact factor: 2.741
Authors: Ibrahim M Sayed; Mohamed A El-Mokhtar; Mahmoud Abdel Rahman Mahmoud; Amal A Elkhawaga; Shereen Gaber; Nermien H Seddek; Lobna Abdel-Wahid; Ahmed M Ashmawy; Enas Ahmed Reda Alkareemy Journal: Infect Drug Resist Date: 2021-01-12 Impact factor: 4.003